Board of Directors
Stéphane Verdood – Non-executive Director; Chairman of the Board
Stéphane Verdood is a non-executive director and chairperson of the board of Apitope, having joined in 2008. He was appointed upon proposal of Vesalius Biocapital. Mr. Verdood has 25 years of experience as a business consultant in the healthcare, pharmaceutical and biotechnology industries. Mr Verdood worked for more than 15 years at Arthur Andersen in the areas of business consulting and the pharmaceutical industry. Mr Verdood merged and reorganised hospitals in Europe and re-engineered European pharmaceutical companies in the areas of research and development, distribution and sales. Mr Verdood founded Andersen Business Consulting in Belgium in 1995, and co-founded Value for Growth in 2001 as venture coach of mainly young biotechnology companies. He assisted more than 10 start-up companies in raising funds. Mr Verdood holds a M.Sc. in commercial engineering as well as an MBA from the University of Leuven.
Keith F. Martin, PhD, MIoD, MRPharmS – Non-executive Director
Keith Martin has enjoyed a career of more than 30 years in both large pharmaceutical companies and early stage biopharmaceutical companies. Dr Martin has held senior positions in research and development and corporate and business development as well as both executive and non-executive board positions with management and leadership roles in the UK, Belgium, the US and Spain. In addition, Dr Martin has developed products from bench to market and realised value through significant licensing deals as well being experienced in grants and venture investment. Dr Martin was CEO of Apitope from April 2006 to October 2018.
Prior to that role, as BTG’s Global Director of Life Sciences, he was responsible for an extensive portfolio of product candidates and licensee marketed products. As Deputy Head of Biology at BASF Pharma, he developed six CNS compounds from the bench through to Phase I and was a key member of the team that developed two products to full market approval in the US and the UK.
Dr Martin began his research career as a PhD student at the University of Bath. He then held a Wellcome Trust Fellowship in Mental Health at Nottingham University Medical School in addition to a NATO Exchange Fellowship to Princeton University Psychology Department and has an extensive list of publications and patents.
Katleen Vandersmissen, PhD - Non-executive Director
Kathleen Vandersmissen is Head of Health & Care at LRM, an investment company which develops and fosters economic growth in Limburg (Belgium). She is a board member of several portfolio companies such as EpiGaN and Bedal. Before LRM, she worked as a consultant for McKinsey & Co. and held positions at Umicore in R&D and Investor Relations.
She graduated summa cum laude from the University of Leuven in Chemistry and obtained a PhD in science from the same university. Later she obtained a MBA in Corporate Finance from the University of Leuven and a post graduate in Corporate Law from HUB-EHSAL.
Ed Rayner, CFA - Non-executive Director
Ed Rayner is an Investment Director at Arix and sits on the boards of Depixus and Pharmaxis. Before joining Arix Bioscience at its inception, Mr Rayner spent 18 years as an equity analyst and Portfolio Manager in Europe and Australia. From 2004 to 2014, he was Head of Research at Alliance Bernstein and then a senior portfolio manager at AMP Capital, a leading Australian investment house with over A$130bn in funds under management, both in Sydney, Australia. At AMP Capital, he managed the growth equity portfolios and launched a small companies fund. As part of his responsibilities he focused on the Healthcare and Biotech sectors.
Prior to his move to Australia, Mr Rayner analysed European equities at UBS Asset Management and JP Morgan Investment Management. He gained an MA in Chemistry and MSc in Management at the University of Oxford and is a Chartered Financial Analyst.
William Jenkins, M.D. - Non-executive Independent Director
Dr Jenkins has a wealth of pharmaceutical industry experience following a 30 year career in clinical medicine and research. He held senior posts at Glaxo as Head of Worldwide Clinical Research and at Ciba-Geigy and then Novartis as Global Head of Medicine, Clinical Development & Regulatory Affairs. During that time he was responsible for the development of drugs such as Zofran, Imigran, Serevent, Diovan & Gleevec. Since 1999, Dr Jenkins has been a consultant to the pharmaceutical industry and a member of several boards including Ablynx, BTG, Tanox, Monogram Biosciences, Eurand, Evotec, Acambis and Consort Medical, as well as a chairman or member of several scientific advisory boards.